Skip to main content

Wegovy News (Page 11)

FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss

On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...

FDA Approves Once-Weekly Wegovy injection for the Treatment of Obesity in Teens Aged 12 Years and Older

New indication based on clinical trial that demonstrated a 16.1% reduction in body mass index (BMI) in teens with obesity treated with Wegovy® (semaglutide) injection 2.4 mg compared to placebo ...

FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity

PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide) injec...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Nonalcoholic Fatty Liver Disease

Wegovy patient information at Drugs.com